Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from BioVie ( (BIVI) ).
On July 17, 2025, BioVie Inc. expanded its Board of Directors from four to six members, appointing Amy S. Chappell, MD, FAAN, and Kameel D. Farag. These seasoned leaders bring significant expertise in neuroscience drug development and corporate finance, which is expected to support BioVie’s mission as it advances its drug candidate bezisterim through Phase 2 trials for early Parkinson’s disease and long COVID, and plans further clinical development for Alzheimer’s disease and ascites programs. The appointments come amid growing momentum for BioVie, which recently presented promising data on bezisterim’s potential at the World Aging and Rejuvenation Conference and initiated its Phase 2 long COVID trial.
The most recent analyst rating on (BIVI) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on BioVie stock, see the BIVI Stock Forecast page.
Spark’s Take on BIVI Stock
According to Spark, TipRanks’ AI Analyst, BIVI is a Underperform.
BioVie faces significant financial challenges as it remains in the R&D phase with no revenue. The strong equity position offers some balance sheet support, but high cash burn and reliance on external financing are concerns. Technical indicators show bearish momentum, and valuation metrics reflect typical pre-revenue biotech risks. Overall, the stock is rated poorly due to these combined factors.
To see Spark’s full report on BIVI stock, click here.
More about BioVie
BioVie Inc. (NASDAQ: BIVI) is a clinical-stage company focused on developing innovative drug therapies for neurological and neurodegenerative disorders such as Alzheimer’s disease, Parkinson’s disease, and long COVID, as well as advanced liver disease. The company is advancing its drug candidate bezisterim, which targets neuroinflammation and insulin resistance, and is also working on BIV201 for liver cirrhosis and ascites.
Average Trading Volume: 55,154
Technical Sentiment Signal: Strong Sell
Current Market Cap: $15.21M
See more insights into BIVI stock on TipRanks’ Stock Analysis page.